1. Home
  2. FDS vs GKOS Comparison

FDS vs GKOS Comparison

Compare FDS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FactSet Research Systems Inc.

FDS

FactSet Research Systems Inc.

HOLD

Current Price

$264.01

Market Cap

9.1B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$167.16

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FDS
GKOS
Founded
1978
1998
Country
United States
United States
Employees
6258
N/A
Industry
Computer Software: Programming Data Processing
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
9.0B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
FDS
GKOS
Price
$264.01
$167.16
Analyst Decision
Hold
Strong Buy
Analyst Count
11
12
Target Price
$284.80
$126.92
AVG Volume (30 Days)
814.3K
822.1K
Earning Date
03-31-2026
04-29-2026
Dividend Yield
1.89%
N/A
EPS Growth
11.79
N/A
EPS
11.16
N/A
Revenue
$1,435,351,000.00
$507,442,000.00
Revenue This Year
$7.16
$23.32
Revenue Next Year
$5.55
$27.43
P/E Ratio
$23.70
N/A
Revenue Growth
6.31
32.33
52 Week Low
$185.00
$73.16
52 Week High
$398.50
$184.00

Technical Indicators

Market Signals
Indicator
FDS
GKOS
Relative Strength Index (RSI) 54.55 72.12
Support Level $245.31 $94.16
Resistance Level $274.72 N/A
Average True Range (ATR) 11.11 7.62
MACD 1.01 0.52
Stochastic Oscillator 40.20 56.01

Price Performance

Historical Comparison
FDS
GKOS

About FDS FactSet Research Systems Inc.

FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: